We lead the field of isotopic metallome with patented composition of matter and methods of use, proprietary drug development platform, and the world's first ISM asset in clinical phase.
Company Presentation
We are an innovative clinical stage company building a pipeline of novel drug candidates based upon our proprietary isotope selective modulation platform.
Our organizational, financial, product development, corporate governance, and other business information is available confidentially upon request.
Current Offering
We currently offer convertible notes under Rule 506(c) only to accredited investors. If you would like to invest, please request a zoom meeting using the form below.
